# Akebia Therapeutics (AKBA) Stock Analysis: A Promising 150% Upside in Healthcare Sector

- Link: https://www.directorstalkinterviews.com/akebia-therapeutics-akba-stock-analysis-a-promising-150-upside-in-healthcare-sector/4121216886
- Published: 2025-09-19T10:28:32+01:00
- Author: Madison Wilson

For investors eyeing the healthcare sector, Akebia Therapeutics, Inc. (NASDAQ: AKBA)
presents a compelling opportunity with its potential upside of 150%. Specializing
in biopharmaceuticals, Akebia focuses on developing and commercializing treatments
for kidney-related diseases. With a current market cap of $784.83 million, the company
is strategically positioned within the burgeoning drug manufacturing industry, particularly
in the specialty and generic segments.

At a current price of $2.96, Akebia shares are trading within a 52-week range of
$1.28 to $4.01. The stock has experienced modest volatility, reflected in a recent
price change of $0.16, which marks a 0.06% increase. For investors considering entry
points, the stock’s technical indicators show a 50-day moving average of $3.37 and
a 200-day moving average of $2.63, with a relative strength index (RSI) of 36.36,
suggesting the stock is approaching oversold territory.

Despite not having a trailing P/E ratio, Akebia’s forward P/E of 11.38 indicates
a potentially attractive valuation for forward-looking investors. However, traditional
valuation metrics such as PEG ratio, price/book, and price/sales are not currently
available, which may require investors to focus more on the company’s growth potential
and strategic developments.

Notably, Akebia’s revenue growth stands at an impressive 43.10%, although the company
is yet to achieve profitability, as evidenced by its negative EPS of -0.18 and a
free cash flow of -$7,423,375. The lack of net income and return on equity metrics
signifies ongoing investment in research and development, particularly in their 
Phase III product, Vafseo (vadadustat), aimed at treating anemia in chronic kidney
disease patients. Additionally, the company’s existing product, Auryxia, offers 
potential revenue streams from its use in managing serum phosphorus levels and treating
iron deficiency anemia.

Akebia’s strategic collaborations, such as its partnership with Mitsubishi Tanabe
Pharma Corporation, bolster its prospects in Asian markets, enhancing its global
reach. This partnership, coupled with a robust pipeline that includes AKB-9090 for
kidney injury and respiratory distress, as well as AKB-10108 for neonatal retinopathy,
underscores the company’s commitment to addressing niche medical needs.

From an analyst perspective, Akebia enjoys strong support with five buy ratings 
and no hold or sell recommendations. The target price range of $6.00 to $10.00, 
with an average target of $7.40, implies significant appreciation potential from
current levels. Investors should weigh this optimism against the inherent risks 
of biotech investments, especially those in clinical development stages.

While Akebia Therapeutics does not offer a dividend yield, thus presenting no immediate
income opportunity, its zero payout ratio reflects a reinvestment strategy aimed
at accelerating growth and product development. This aligns with the company’s long-
term vision of expanding its therapeutic offerings and market presence.

For investors with a tolerance for risk and a focus on growth, Akebia Therapeutics
stands out as a potentially rewarding investment in the healthcare sector. With 
its innovative product pipeline and strategic collaborations, the company is well-
positioned to capitalize on future advancements in kidney disease treatment, offering
a promising avenue for portfolio diversification.

Share on: